All In Biotech

Free tool

FAERS Monitor: Onfi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202067 or its brand name (Onfi, Clobazam). Reports on generic versions are filed under their own applications.

Reports

24,918

Serious

19,680

79% of reports

Hospitalization

8,481

Death reported

1,592

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure5,137
  • drug ineffective3,354
  • off label use2,341
  • somnolence1,987
  • drug interaction1,200
  • fatigue1,179
  • epilepsy870
  • condition aggravated859
  • generalised tonic-clonic seizure774
  • status epilepticus738
  • pneumonia719
  • aggression715
  • product use in unapproved indication713
  • fall691
  • decreased appetite670

Reports by year received

View as table
YearReports
200446
200573
200669
200784
2008111
2009127
2010168
2011140
2012656
2013723
2014787
2015997
20161,142
20171,303
20181,257
20192,057
20201,917
20212,650
20222,014
20232,184
20242,401
20252,226
20261,785

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,241 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
status epilepticusSignal73859.054.839,268
generalised tonic-clonic seizureSignal77441.438.529,048
seizureSignal5,13739.238.3183,894
epilepsySignal87024.723.119,221
aggressionSignal71512.211.47,266
somnolenceSignal1,9878.48.112,947
drug interactionSignal1,2006.46.15,492
decreased appetiteSignal6702.42.3572
product use in unapproved indicationSignal7132.42.3605
condition aggravatedSignal8592.42.2700
off label useSignal2,3412.32.21,710
drug ineffectiveSignal3,3542.22.12,197
pneumonia7191.91.7297
fall6911.81.6226
fatigue1,1791.31.274

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.